Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 377 across all filing types
Latest filing 2021-06-03 Annual Report
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Annual Report as of December 2020 (Courtesy English Translation)
Annual Report Classification · 100% confidence The document is titled 'Financial Report at 31 December 2020' and contains a comprehensive table of contents detailing consolidated financial statements, separate financial statements, notes to the accounts, and a directors' report. It covers the full fiscal year and provides detailed financial data, which aligns with the definition of an Annual Report (10-K). FY 2020
2021-06-03 English
Press release Shareholders' meeting decisions as of 2021
AGM Information Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE' and details the resolutions passed by the 'SHAREHOLDERS' MEETING 2021 PHILOGEN S.P.A.'. Key items approved include the 2020 Financial Statements, the Remuneration Policy, and an Incentive Plan. The text summarizes the outcomes of a general meeting where shareholders voted on corporate matters. This content strongly aligns with the purpose of an Annual General Meeting (AGM) and the materials presented there. While it mentions financial statements, the document itself is the announcement of the meeting's results, not the full 10-K or IR. Therefore, the most appropriate classification is AGM-R (AGM Information).
2021-05-31 English
Comunicato Deliberazioni Assemblea 2021
AGM Information Classification · 99% confidence The document is titled 'ASSEMBLEA DEGLI AZIONISTI 2021 PHILOGEN S.P.A.' and details the resolutions passed by the Shareholders' Meeting (Assemblea degli Azionisti) in both ordinary and extraordinary sessions. Key approvals include the 2020 Financial Statements (Bilancio di esercizio 2020), the Remuneration Policy (Politica di Remunerazione), and the approval of a new stock grant incentive plan ('Piano di stock grant 2024-2026'). The text explicitly discusses shareholder voting and meeting outcomes, which aligns directly with the purpose of an Annual General Meeting (AGM). Although it mentions the approval of financial statements and remuneration reports, the document itself is the announcement/summary of the meeting's proceedings and resolutions, making AGM-R the most appropriate classification.
2021-05-31 Italian
COMUNICAZIONE AI SENSI DELL’ART. 85-BIS, COMMA 4-BIS, DEL REGOLAMENTO EMITTENTI
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "COMUNICAZIONE AI SENSI DELL'ART. 85-BIS, COMMA 4-BIS, DEL REGOLAMENTO EMITTENTI" (Communication pursuant to Art. 85-bis, paragraph 4-bis, of the Issuers' Regulation) and is dated May 21, 2021. It explicitly states that it is being issued in view of the Shareholders' Meeting ('Assemblea degli Azionisti') convened for May 31, 2021. The core content is the communication of the total number of voting rights and the composition of the share capital, which is a mandatory disclosure related to a general meeting. This type of disclosure, especially when tied directly to the voting structure ahead of a meeting, strongly suggests a filing related to the Annual General Meeting (AGM) or the information required for it. Since the document provides specific voting rights information required before a general meeting, it aligns best with AGM-R (AGM Information) or potentially DEF 14A (Proxy Statement), but given the focus on voting rights calculation immediately preceding the meeting, AGM-R is the most precise fit among the provided options for pre-meeting procedural disclosures.
2021-05-21 Italian
Comunicazione sull'aggiornamento sui progressi della pipeline (versione in inglese)
Earnings Release Classification · 98% confidence The document is titled "Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress". It details clinical trial updates (NidlegyTM, Fibromun, Darleukin, etc.), manufacturing progress, and a brief financial update (cash position, IPO in March 2021). The date is May 12, 2021, which corresponds to the period immediately following the first quarter (Q1) of 2021. This content structure—a summary of recent operational and financial performance for a specific short period (Q1)—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR), as it focuses on highlights and pipeline progress rather than detailed, standardized financial statements typical of those comprehensive filings. It also mentions a webinar to discuss the news, which is common for ERs. Q1 2021
2021-05-12 Italian
Comunicazione sull' aggiornamento sui progressi della pipeline
Earnings Release Classification · 98% confidence The document is titled "Philogen annuncia i risultati del primo trimestre 2021 e fornisce un aggiornamento sui progressi della pipeline" (Philogen announces first quarter 2021 results and provides an update on pipeline progress). It details the status of various clinical trials (Phase I, II, III) for drug candidates (NidlegyTM, Fibromun, Darleukin, etc.) and provides a financial update, noting cash reserves of approximately 120 million euros following a successful IPO on March 3, 2021. This content structure—periodical financial highlights combined with detailed operational/pipeline updates—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it explicitly mentions 'risultati del primo trimestre 2021' (first quarter 2021 results) and provides key financial figures alongside operational updates, it aligns best with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). While it contains substantial detail, the focus on quarterly results points strongly to ER, which often precedes a more comprehensive Management Discussion & Analysis (MDA) or Interim Report (IR). Given the context of announcing quarterly results, ER is the most precise fit among the options provided. Q1 2021
2021-05-12 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.